Metabolic syndrome (MetS), the concomitant occurrence of multiple metabolic irregularities, has been associated with a significant risk of future diabetes mellitus, cardiovascular disease, and mortality. Nevertheless, the manner in which the syndrome evolves and the manner in which the future trajectories of disease develop remained uncertain. Using data from 3708 participants of the Framingham Offspring Study, we evaluated in adults the distribution and progression of the MetS and its components, the trajectories followed by those entering the MetS, and the potential effect of individual trajectories on the subsequent development of cardiovascular disease and mortality. MetS was defined according to the Adult Treatment Panel III criteria. After 10 years of follow-up, the prevalence of MetS almost doubled. Hyperglycemia and central obesity experienced the highest increase. High blood pressure was most frequently present when a diagnosis of MetS occurred (77.3%), and presence of central obesity conferred the highest risk of developing MetS (odds ratio, 4.75; 95% confidence interval, 3.78 to 5.98). Participants who entered the MetS having a combination of central obesity, high blood pressure, and hyperglycemia had a 236% increase in incident cardiovascular events and a 309% increased risk of mortality. MetS is highly prevalent and is increasing dramatically; however, not all individuals who are diagnosed with MetS enter the diagnosis with the identical combination of factors, and we identified 2 particular combinations of components that confer higher risks of incident cardiovascular disease and mortality. Intense efforts are required to identify populations with these particular combinations and to provide them with adequate treatment at early stages of disease. See p 1943.
Chronic Pulmonary Artery Pressure Elevation Is Insufficient to Explain Right Heart Failure
The presence of right heart failure increases the morbidity and mortality associated with pulmonary hypertension. The mechanisms by which right heart failure occurs in pulmonary hypertension are uncertain; however, the degree and duration of pressure overload do not explain sufficiently why the right ventricle (RV) ultimately dilates and fails. The present study shows in a rodent model that the RV is tolerant to chronic progressive pressure overload as long as this pressure overload is not associated with angioproliferative pulmonary vascular disease. This finding suggests that molecular, cellular, and hemodynamic lung-heart interactions explain the transition from compensated hypertrophy to RV dilatation and failure in pulmonary hypertension. It is further shown that important features of the failing RV include a loss of capillaries in the microcirculation and increased fibrosis. These structural changes are associated with evidence of oxidative stress and a biochemical uncoupling of hypoxia-induced factor-1␣ protein stabilization and vascular endothelial growth factor transcription. Moreover, this study shows that a dietary intervention can prevent RV dysfunction and pathological remodeling in the setting of persistent pressure overload. By inducing nuclear factor E2-related factor 2 and heme-oxygenase 1, the herbal supplement Protandim prevented a loss of myocardial capillaries, reduced the degree of RV fibrosis, and prevented RV dilation and loss of myocardial contractility. See p 1951.
Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major
Patients with transfusion-dependent anemias such as thalassemia major die primarily of heart failure caused by myocardial siderosis. Significant recent advances in the prevention of cardiac mortality include the robust identification of the level of iron loading in the heart with T2* cardiovascular magnetic resonance and improved treatments to remove cardiac iron quickly while reducing the toxicity of iron-mediated reactive oxygen species. However, the drive to treat myocardial siderosis aggressively has not been guided by an understanding of the clinical outcomes in relation to the severity of myocardial siderosis. In this multicenter prognostic study of thalassemia major patients, we show that the risk of progression to heart failure is present dominantly with myocardial T2* Ͻ10 ms and that the risk climbs steeply with further reductions in T2* (increasing myocardial siderosis). Likewise, there is increased likelihood of progression to both atrial and ventricular arrhythmias with increasing myocardial siderosis but with a higher T2* threshold, indicating that other factors such as increased atrial sensitivity to iron and chronic atrial stretch from raised cardiac output may be involved. These data form a new bedrock for risk assessment in clinical practice for the need to treat myocardial siderosis and in particular show that cardiac T2* is a significantly better predictor of cardiac events than the established measures of liver iron and serum ferritin. T2* cardiovascular magnetic resonance has significant potential to lead to the eradication of heart failure-related death in transfusion-dependent anemias when it is available and effective cardiac chelation can be instituted and maintained. See p 1961.
Detection of Myocardial Damage in Patients With Sarcoidosis
In patients with sarcoidosis, sudden death is a leading cause of mortality, which may represent clinically unrecognized cardiac involvement. Delayed-enhancement cardiovascular magnetic resonance (DE-CMR) can detect very small amounts of myocardial damage; therefore, we sought to evaluate the usefulness of DE-CMR for identifying cardiac involvement in 81 consecutive patients with biopsy-proven extracardiac sarcoidosis. When compared with a standard clinical evaluation, which included 12-lead ECG and at least 1 dedicated non-CMR cardiac study (echocardiography, radionuclide scintigraphy, or cardiac catheterization), DE-CMR identified cardiac involvement at a Ͼ2-fold higher rate. Patients were also followed up for 21 months on average for major adverse events (death, defibrillator shock, or pacemaker requirement). During follow-up, patients with myocardial damage on DE-CMR had a 9-fold higher rate of adverse events and an 11.5-fold higher rate of cardiac death than patients without damage. On the basis of these findings, we believe that DE-CMR is more than twice as sensitive for cardiac involvement as currently used standard methods. Myocardial damage detected by DE-CMR also appears to be associated with future adverse events, including cardiac death, but events were few, and this needs confirmation in a larger cohort. See p 1969.
Comparison of Plaque Sealing With Paclitaxel-Eluting Stents Versus Medical Therapy for the Treatment of Moderate Nonsignificant Saphenous Vein Graft Lesions: The Moderate VEin Graft LEsion Stenting With the Taxus Stent and Intravascular Ultrasound (VELETI) Pilot Trial
The presence of moderate saphenous vein graft (SVG) lesions is a major predictor of cardiac events late after coronary artery bypass
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Original Research Put Into Perspective for the Practicing Clinician Volume 120 Ⅲ Number 20 Ⅲ November 17, 2009 grafting. We designed a pilot study to test the hypothesis of sealing moderate nonsignificant SVG lesions with paclitaxel-eluting stents (PES) to prevent atherosclerosis progression at the level of the moderate SVG lesion while not inducing any deleterious effect on the atherosclerotic process of the nonstented SVG segments. Patients with at least 1 moderate SVG lesion (30% to 60% diameter stenosis) were randomized either to stenting the moderate SVG lesion with a PES (nϭ30, PES group) or to medical treatment alone (nϭ27, medical treatment group). Patients had an angiographic and intravascular ultrasound evaluation of the SVG at baseline and at 12-month follow-up. Mean time from coronary artery bypass grafting was 12Ϯ6 years, and mean low-density lipoprotein cholesterol level was 73Ϯ31 mg/dL. Significant disease progression occurred in the medical treatment group at the level of the moderate SVG lesion as evaluated by angiography and intravascular ultrasound (PϽ0.01 versus baseline; PϽ0.01 versus PES group), leading to a severe flow-limiting lesion or SVG occlusion in up to 22% of the patients compared with none in the PES group (Pϭ0.014). There were no cases of restenosis or stent thrombosis, and no significant atherosclerosis progression occurred at the nonstented SVG segments. At 12-month follow-up, the cumulative incidence of major adverse cardiac events related to the target SVG was 19% in the medical treatment group versus 3% in the PES group (Pϭ0.091). In conclusion, old and moderately diseased SVGs presented a significant and very rapid (within 12 months) disease progression at the sites exhibiting moderate lesions despite optimal control of lowdensity lipoprotein cholesterol levels, and sealing such moderate lesions with PES prevented this process without inducing any deleterious effect on the atherosclerotic disease of nonstented SVG segments. This pilot study provides early evidence that plaque sealing as a new strategy for the treatment of a challenging subset of patients after coronary artery bypass grafting should be explored further. See p 1978.
C-Reactive Protein and the Risk of Stent Thrombosis and Cardiovascular Events After Drug-Eluting Stent Implantation
High-sensitivity C-reactive protein (CRP) has been postulated to be a hemostatic risk factor predicting atherothrombosis. However, the association between CRP and stent thrombosis after drug-eluting stent implantation has not been defined. We prospectively investigated whether CRP levels were associated with the risk of stent thrombosis and long-term clinical outcomes and assessed the incremental usefulness of CRP for predicting these events beyond clinical and angiographic risk assessment in 2691 patients who received drug-eluting stent implantation with a median follow-up of 3.9 years. In multivariable Cox proportional-hazards models, elevated levels of CRP were significantly associated with increased risk of stent thrombosis (definite or probable; hazard ratio, 3.86; 95% confidence interval, 1.82 to 8.18; PϽ0.001). There were also independent associations of elevated CRP levels with late stent thrombosis (hazard ratio, 3.88; 95% confidence interval, 1.75 to 8.61; PϽ0.001). Elevated CRP levels significantly predicted the risks of death (hazard ratio, 1.61; 95% confidence interval, 1.13 to 2.28; Pϭ0.008), myocardial infarction (hazard ratio, 1.63; 95% confidence interval, 1.25 to 2.12; Pϭ0.001), and death or MI (hazard ratio, 1.61; 95% confidence interval, 1.29 to 2.00; PϽ0.001). The incorporation of CRP into a model with patient, lesion, and procedural factors resulted in a significant increase in the C statistic for the prediction of stent thrombosis, myocardial infarction, and the composite of death or myocardial infarction. Our data support the independent association of CRP with stent thrombosis and major cardiovascular events in patients receiving drug-eluting stents. Inflammatory risk assessment with CRP as an adjunct to clinical and angiographic risk factors may be useful for identifying patients at high risk who could then be targeted for preventive measure. See p 1987.
Oral Anti-CD3 Antibody Treatment Induces Regulatory T Cells and Inhibits the Development of Atherosclerosis in Mice
Atherosclerosis is a chronic inflammatory condition of the arterial wall involving immune cells and their releasing molecules. This important notion has led to a quest to develop an antiinflammatory and immune therapy for prevention of atherosclerosis in clinical patients. Accumulating evidence suggests that several subsets of regulatory T cells (Tregs) inhibit atherosclerosis development through the downregulation of activated T-cell responses. Recent studies have demonstrated that parenteral administration of anti-CD3-specific antibody restores long-lasting self-tolerance and is effective in autoimmune diabetes in mice and humans, partly because of the expansion of CD4 ϩ CD25 ϩ Tregs. Interestingly, orally administered anti-CD3 antibody has been shown to prevent systemic autoimmunity through induction of novel Tregs expressing latencyassociated peptide (LAP) on their surface in the gut. In the present study, we first show that oral anti-CD3 antibody treatment attenuates atherosclerotic lesion formation and plaque inflammation and that this suppression is associated with an increase in the number of CD4 ϩ CD25 -LAP ϩ Tregs and, unexpectedly, CD4 ϩ CD25 ϩ Foxp3 ϩ Tregs, which are possibly induced in the gut-associated lymphoid tissue and migrate into other lymphoid organs or atherosclerotic plaques, subsequently leading to suppression of T-helper type 1 and type 2 immune responses through a transforming growth factor-␤dependent mechanism. Our data indicate that oral administration of anti-CD3 antibody seems to be safe and easy to apply and therefore could be used as a promising therapeutic approach for atherosclerotic vascular disorders. Clinical studies are required. See p 1996.
Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials
Patients receiving antithrombotic therapy for the treatment of acute coronary syndrome who develop major bleeding are at increased risk of nonfatal and fatal cardiovascular outcomes compared with those who do not develop bleeding. Whether a similar association exists between major bleeding and adverse outcomes in patients receiving anticoagulants for the prevention of venous thromboembolism is unknown. Our analyses of an individual patient database involving Ͼ13 000 surgical and medical patients receiving fondaparinux or control for the prevention of venous thromboembolism showed that patients who develop major bleeding have an almost 7-fold increased risk of death. Although fondaparinux, compared with control, was associated with a significant increase in the risk of major bleeding, it was associated with numerically fewer deaths both in patients who experienced major bleeding and in those who did not experience major bleeding. Our analyses confirm that major bleeding in hospitalized patients is a powerful predictor of death. The trend of reduced mortality with fondaparinux despite the increase in major bleeding underscores the importance of using proven effective thromboprophylaxis strategies according to the overall results of randomized controlled trials, even if drugs increase the risk of bleeding. Further investigation is required to understand the determinants of major bleeding and mechanisms that mediate the increase in mortality. See p 2006.
